GLP-1 Makers Paid More Than 270,000 US Doctors, Federal Disclosures Show

Federal transparency data shows Eli Lilly and Novo Nordisk collectively paid more than 270,000 US healthcare providers to promote their GLP-1 weight-loss drugs, with at least one physician receiving as much as $1 million — one of the largest promotional footprints ever documented for a drug class.

What Happened

An analysis of federal Open Payments disclosures, reported by multiple outlets in September 2026, found the two manufacturers together compensated over a quarter-million American prescribers as GLP-1 sales climbed. The payments covered consulting, speaking engagements, meals and travel connected to drugs such as Ozempic, Wegovy, Zepbound and Mounjaro.

The figure lands amid growing scrutiny of how weight-loss drugs are promoted. Investigative reporting has previously found that doctors who receive money from a manufacturer tend to prescribe more of that manufacturer's products, and US senators have opened inquiries into manufacturer-backed direct-to-consumer prescribing platforms.

Who Is Affected

• Patients, who often have no easy way to learn whether the prescriber recommending a GLP-1 has financial ties to its maker
• Telehealth prescribers, whose volume-driven models are now under a public transparency spotlight
• Guideline writers, after analyses flagged potential manufacturer influence in adolescent GLP-1 treatment guidance
• Policymakers weighing whether disclosure rules need stronger enforcement

Timeline

• 2022–2024: GLP-1 prescriptions surge; promotional payments to prescribers climb in step
• 2025–2026: Competition intensifies as new oral options reach the market and sales growth normalizes
• September 2026: The quarter-million-prescriber figure is reported, drawing on the federal disclosure database
• Ongoing: Congressional scrutiny of manufacturer marketing tactics continues

What This Means for Researchers

The disclosures are a reminder to weigh who funds the information, not just what it says. Speaker-slide claims, sponsored symposium content and even guideline language deserve conflict-of-interest screening before being cited. PepsReview takes no manufacturer funding, and we treat industry-sponsored material with the skepticism it requires. The Open Payments database itself is public — transparency tools exist for those willing to use them.

How to Verify Your Peptides

Prescriber transparency is one layer of protection; product integrity is another. Counterfeit and mislabeled GLP-1 products remain widespread, and no disclosure regime fixes a bad vial. Learn what genuine analysis looks like in our guide to how peptide testing works, review HPLC versus LC-MS methods, and see our semaglutide testing and purity guide for the compound at the center of this market.

Safe Alternatives

Legitimate treatment and research paths exist outside the marketing noise. Our peptide profiles summarize the evidence for GLP-1 compounds, and our vendor directory highlights suppliers that publish verifiable third-party testing records.

Sources

Federal transparency disclosures and industry reports, September 2026.